Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
118
Recruiting Now
118
Top Conditions in Phase 2 / Phase 3
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT01949129 Phase 2, Phase 3
Recruiting
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lym...
Condition
Acute Lymphoblastic Leukaemia
Enrollment
1,800 pts
Location
Argentina, Australia, Austria
Sponsor
St. Anna Kinderkrebsforschung
NCT07389616 Phase 2, Phase 3
Recruiting
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Pro...
Condition
Peripheral T Cell Lymphoma
Enrollment
40 pts
Location
China
Sponsor
Shanghai General Hospital, Sha
NCT04932577 Phase 2, Phase 3
Recruiting
Faecal Microbiota Transplantation for Liver Cirrhosis
Condition
Liver Cirrhosis
Enrollment
220 pts
Location
Denmark
Sponsor
University of Aarhus
NCT07908381 Phase 2, Phase 3
Recruiting
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Plac...
Condition
RSV
Enrollment
860 pts
Location
United States
Sponsor
Enanta Pharmaceuticals, Inc
NCT06191965 Phase 2, Phase 3
Recruiting
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunct...
Condition
Schizophrenia and Related Disorders
Enrollment
100 pts
Location
United States, Switzerland
Sponsor
Mclean Hospital
NCT05935553 Phase 2, Phase 3
Recruiting
Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence
Condition
Benzodiazepine Dependence
Enrollment
93 pts
Location
France
Sponsor
Hospices Civils de Lyon
NCT05288777 Phase 2, Phase 3
Recruiting
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
Condition
Breast Cancer
Enrollment
45 pts
Location
United States
Sponsor
University of Virginia
NCT05011266 Phase 2, Phase 3
Recruiting
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention i...
Condition
Opioid-use Disorder
Enrollment
180 pts
Location
United States
Sponsor
New York State Psychiatric Ins
NCT03804931 Phase 2, Phase 3
Recruiting
Fecal Microbiota Transplantation for Ulcerative Colitis
Condition
Ulcerative Colitis
Enrollment
120 pts
Location
China
Sponsor
Guangzhou First People's Hospi
NCT05255302 Phase 2, Phase 3
Recruiting
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer ...
Condition
Metastatic NSCLC
Enrollment
1,360 pts
Location
France
Sponsor
Intergroupe Francophone de Can
NCT07272772 Phase 2, Phase 3
Recruiting
Colon Cancer Diagnosis With FAPI-PET Imaging
Condition
Colon Cancer
Enrollment
100 pts
Location
Finland
Sponsor
Turku University Hospital
NCT07643623 Phase 2, Phase 3
Recruiting
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherap...
Condition
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment
720 pts
Location
China
Sponsor
Innovent Biopharmaceutical Tec
NCT04333537 Phase 2, Phase 3
Recruiting
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Pat...
Condition
Buccal Mucosa Squamous Cell Carcinoma
Enrollment
686 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT07176546 Phase 2, Phase 3
Recruiting
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Condition
Granulomatosis With Polyangiitis
Enrollment
30 pts
Location
United States
Sponsor
Robert Spiera, MD
NCT06207253 Phase 2, Phase 3
Recruiting
The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament
Condition
Endodontic Disease
Enrollment
48 pts
Location
Egypt
Sponsor
British University In Egypt
NCT07722611 Phase 2, Phase 3
Recruiting
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-...
Condition
Polycythemia Vera
Enrollment
380 pts
Location
United States, Canada, Israel
Sponsor
Merck Sharp & Dohme LLC
NCT02448992 Phase 2, Phase 3
Recruiting
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Pos...
Condition
Non-Small-Cell Lung Cancer (NSCLC)
Enrollment
90 pts
Location
Taiwan
Sponsor
Chang Gung Memorial Hospital
NCT07047612 Phase 2, Phase 3
Recruiting
ICP-332 in Subjects With Non-segmental Vitiligo
Condition
Non Segmental Vitiligo
Enrollment
603 pts
Location
China
Sponsor
Beijing InnoCare Pharma Tech C
Page 5 of 5 — 118 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology